# PCA062 in pCAD-positive Tumors.

> **NCT02375958** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Head & Neck Cancer
- Esophageal Cancer

## Interventions

- **DRUG:** PCA062

## Key facts

- **NCT ID:** NCT02375958
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-15
- **Primary completion:** 2018-07-17
- **Final completion:** 2018-07-17
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02375958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02375958, "PCA062 in pCAD-positive Tumors.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02375958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*